VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
Titel:
VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
Auteur:
André, T. Falcone, A. Shparyk, Y. Moiseenko, F.V. Marques, E. Polo Csoszi, T. Bragagnoli, A. Campos Liposits, G. Chmielowska, E. Aubel, P. Martín-Fernández, L. Fougeray, R. Causse-Amellal, N. Saunders, M.P.